Page 176 - 2019_04-Haematologica-web

S.E. Sylvan et al.
patients, regardless of comorbidity,45,46 also elderly, comorbid patients should preferably undergo cytogenetic analysis and receive treatments for adequate disease con- trol. Hence, we conclude that alternative modern, effec- tive first-line treatment alternatives must be offered to elderly comorbid patients. Our study also raises the ques- tion as to whether drugs other than CLB, even if com- bined with a CD20 antibody,47 should be considered as the chemotherapy approach in the standard-of-care arm in pivotal clinical trials. Finally, we have also demonstrat- ed inter-regional differences in drug and FISH usage, and that outcome may vary in different parts of the country despite regular updates on generally available national
CLL guidelines; findings which need to be further inves- tigated in detail.
Funding
This study was a collaboration within the Swedish CLL group and was supported by grants from AFA Insurance (Ref no: 130054), SLL/ALF (Ref no: 20150070), Blodcancerfonden 2016, Dr Åke Olsson Foundation (Ref no: 2-791/2016), SLL/KI Högre klinisk forskare 2018/2019 (K2894-2016), Svenska Läkaresällskapet (SLS-406961), The Gilead Sciences Nordic Fellowship Programme 2015 (LH), The Swedish Cancer Society (Ref no: 150930, 160534). We thank Ms Leila Relander for editorial assistance.
References
1. Asklid A, Winqvist M, Eketorp Sylvan S, et al. Outcomes of second-line treatment in chronic lymphocytic leukemia - a popula- tion-based study from a well defined geo- graphical region between 2003 and 2013. Leuk Lymphoma. 2017;58(5):1219-1223.
2. Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50-54.
3. Svenska KLL gruppen. https://www.cancer- centrum.se/syd/cancerdiagnoser/blod-lym- fom-myelom/kronisk-lymfatisk-leukemi- kll/vardprogram/. Regionalt cancercentrum Stockholm och Gotland. 2016.
4. Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer death rates in US congres- sional districts. CA Cancer J Clin. 2015;65(5):339-344.
5. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for diagnosis, indications for treatment, response assessment and sup- portive management of chronic lymphocyt- ic leukemia. Blood. 2018;131(25):2745-2760.
6. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-1174.
7. Cramer P, Fink AM, Busch R, et al. Second- line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and ritux- imab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma. 2013; 54(8):1821-1822.
8. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open- label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-942.
9. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with ritux- imab for previously untreated patients with chronic lymphocytic leukemia: a multicen- ter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216.
10. Goede V, Fischer K, Busch R, et al.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
22. Lewis J, Kerridge I, Lipworth W. Use of Real- World Data for the Research, Development, and Evaluation of Oncology Precision Medicines. JCO Precision Oncology. 2017:1-
11. Hillmen P, Robak T, Janssens A, et al. 11.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a ran- domised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873-1883.
12. Michallet AS, Aktan M, Hiddemann W, et al. Rituximab plus bendamustine or chlo- rambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open- label MABLE study. Haematologica. 2018;103(4):698-706.
13. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247- 3254.
14. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lympho- cytic leukemia. J Clin Oncol. 2010; 28(29):4473-4479.
15. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
16. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identi- fies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121(8):1403-1412.
17. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
18. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
19. Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014; 370(24):2352-2354.
20. Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol 2018; 182(4):504-512.
21. O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refrac- tory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409-1418.
23. Loberiza FR Jr, Cannon AJ, Weisenburger DD, et al. Survival disparities in patients with lymphoma according to place of resi- dence and treatment provider: a population- based study. J Clin Oncol. 2009; 27(32):5376-5382.
24. The World Medical Association. 64th WMA General Assembly Fortaleza Brazil, October 2013. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 2018 [cited; Available from: https://www.wma.net/poli- cies-post/wma-declaration-of-helsinki-ethi- cal-principles-for-medical-research-involv- ing-human-subjects/
25. Bellosillo B, Pique M, Barragan M, et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lym- phocytic leukemia cells. Blood. 1998; 92(4):1406-1414.
26. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol. 2003;31(9):779-783.
27. Chae YK, Trinh L, Jain P, et al. Statin and aspirin use is associated with improved out- come of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(9):1424-1426.
28. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
29. Socialstyrelsen. http://www.social- styrelsen.se/register/dodsorsaksregistret.
30. Lewis J, Kerridge I, Lipworth W. Use of real-
world data for the research, revelopment, and evaluation of oncology precision medi- cines. JCO Precision Oncology. 2017:1-11.
31. Lewis JR, Lipworth WL, Kerridge IH, Day RO. The economic evaluation of person- alised oncology medicines: ethical chal- lenges. Med J Aust. 2013;199(7):471-473.
32. Huang SJ, Lee LJ, Gerrie AS, et al. Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred
804
haematologica | 2019; 104(4)